A detailed history of Israel Englander (Millennium Management LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 27,400 shares of SRPT stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,400
Previous 19,500 40.51%
Holding current value
$3.51 Million
Previous $2.52 Million 71.51%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$113.33 - $163.85 $34.2 Million - $49.5 Million
-301,872 Reduced 34.53%
572,275 $90.4 Million
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $21.6 Million - $32.6 Million
230,009 Added 35.71%
874,147 $113 Million
Q4 2023

Feb 14, 2024

BUY
$67.31 - $124.76 $32 Million - $59.3 Million
475,231 Added 281.36%
644,138 $62.1 Million
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $44.1 Million - $65.1 Million
-414,017 Reduced 71.02%
168,907 $19.3 Million
Q1 2023

May 15, 2023

BUY
$117.53 - $155.99 $21.3 Million - $28.2 Million
180,933 Added 45.01%
582,924 $80.3 Million
Q4 2022

Feb 14, 2023

SELL
$100.86 - $132.13 $31.3 Million - $41.1 Million
-310,747 Reduced 43.6%
401,991 $52.1 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $29.3 Million - $46.2 Million
387,072 Added 118.86%
712,738 $78.8 Million
Q2 2022

Aug 15, 2022

BUY
$62.69 - $88.44 $9.67 Million - $13.6 Million
154,251 Added 89.99%
325,666 $24.4 Million
Q1 2022

May 16, 2022

SELL
$63.15 - $90.42 $10.6 Million - $15.2 Million
-168,204 Reduced 49.53%
171,415 $13.4 Million
Q4 2021

Feb 14, 2022

BUY
$77.28 - $99.42 $17.3 Million - $22.3 Million
223,967 Added 193.66%
339,619 $30.6 Million
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $3.17 Million - $4.44 Million
48,062 Added 71.11%
115,652 $10.7 Million
Q2 2021

Aug 16, 2021

SELL
$69.38 - $86.75 $21 Million - $26.2 Million
-302,593 Reduced 81.74%
67,590 $5.25 Million
Q1 2021

May 17, 2021

BUY
$72.25 - $168.95 $17.1 Million - $40 Million
236,994 Added 177.94%
370,183 $27.6 Million
Q4 2020

Feb 16, 2021

BUY
$125.56 - $178.74 $12.9 Million - $18.4 Million
102,837 Added 338.81%
133,189 $22.7 Million
Q3 2020

Nov 16, 2020

SELL
$127.12 - $172.34 $12 Million - $16.3 Million
-94,414 Reduced 75.67%
30,352 $4.26 Million
Q2 2020

Aug 14, 2020

SELL
$93.0 - $171.7 $2.32 Million - $4.29 Million
-24,978 Reduced 16.68%
124,766 $20 Million
Q1 2020

May 14, 2020

SELL
$82.38 - $131.64 $649,401 - $1.04 Million
-7,883 Reduced 5.0%
149,744 $14.6 Million
Q4 2019

Feb 14, 2020

BUY
$76.53 - $135.58 $7.39 Million - $13.1 Million
96,586 Added 158.23%
157,627 $20.3 Million
Q3 2019

Nov 14, 2019

SELL
$72.81 - $156.91 $1.42 Million - $3.06 Million
-19,504 Reduced 24.22%
61,041 $4.6 Million
Q2 2019

Aug 15, 2019

SELL
$112.21 - $151.95 $959,395 - $1.3 Million
-8,550 Reduced 9.6%
80,545 $12.2 Million
Q2 2019

Aug 14, 2019

SELL
$112.21 - $151.95 $15.3 Million - $20.8 Million
-136,659 Reduced 60.53%
89,095 $3.34 Million
Q1 2019

May 14, 2019

BUY
$106.67 - $151.68 $7.93 Million - $11.3 Million
74,349 Added 49.11%
225,754 $26.9 Million
Q4 2018

Feb 14, 2019

SELL
$97.32 - $148.76 $46.1 Million - $70.4 Million
-473,335 Reduced 75.77%
151,405 $16.5 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $26.9 Million - $37.7 Million
-233,667 Reduced 27.22%
624,740 $101 Million
Q2 2018

Aug 14, 2018

BUY
$71.74 - $153.69 $36.4 Million - $78 Million
507,588 Added 144.69%
858,407 $113 Million
Q1 2018

May 15, 2018

SELL
$54.02 - $82.27 $24.4 Million - $37.1 Million
-451,152 Reduced 56.26%
350,819 $26 Million
Q4 2017

Feb 14, 2018

SELL
$47.64 - $56.75 $18.1 Million - $21.6 Million
-380,297 Reduced 32.17%
801,971 $44.6 Million
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $42.2 Million - $55.7 Million
1,182,268
1,182,268 $53.6 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11.2B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.